Active ingredientOmarigliptinCat. No. P-O020-001CAS 1226781-44-7Family · Pharmaceutical analytical standards
Omarigliptin
A DPP-4 inhibitor (gliptin) for type 2 diabetes, approved in Japan in 2015: unlike most gliptins, it has a very long duration of action. This family brings together the active ingredient and other impurities.
Did you know?It was not the first gliptin of this kind: trelagliptin had preceded it in Japan by a few months. In 2016 its development for the United States and Europe was stopped for commercial reasons, not for safety or efficacy reasons.
Go to the active ingredient →Active ingredientOmarigliptinCat. No. P-O020-001CAS 1226781-44-7
ImpurityOmarigliptin Impurity 1Cat. No. P-O020-002CAS 1211594-55-6
ImpurityOmarigliptin Impurity 2Cat. No. P-O020-003CAS 1588322-50-2
ImpurityOmarigliptin Impurity 3Cat. No. P-O020-004CAS 951127-31-4
ImpurityOmarigliptin Impurity ECat. No. P-O020-005CAS 1456616-43-5
ImpurityOmarigliptin Impurity 4Cat. No. P-O020-006CAS 951127-25-6
ImpurityOmarigliptin Impurity CCat. No. P-O020-007CAS 1456616-42-4
ImpurityOmarigliptin Impurity DCat. No. P-O020-008CAS 1456616-44-6No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.